Approved biosimilar ranibizumab-a global update
Eye (Lond)
.
2023 Feb;37(2):200-202.
doi: 10.1038/s41433-022-02246-5.
Epub 2022 Sep 16.
Authors
Ashish Sharma
1
,
Mineo Kondo
2
,
Chiharu Iwahashi
3
,
Nikulaa Parachuri
4
,
Nilesh Kumar
5
,
Francesco Bandello
6
,
Anat Loewenstein
7
,
Baruch D Kuppermann
8
Affiliations
1
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, Tamil Nadu, India. drashish79@hotmail.com.
2
Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu, Japan.
3
Department of Ophthalmology, Kindai University of Medicine, Osaka, Japan.
4
Sankara Eye Hospital, Coimbatore, Tamil Nadu, India.
5
Madhavi Netralaya, Ara, Bihar, India.
6
University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy.
7
Division of Ophthalmology, Tel Aviv Medical, Tel Aviv University, Tel Aviv, Israel.
8
Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA.
PMID:
36114290
PMCID:
PMC9873906
DOI:
10.1038/s41433-022-02246-5
No abstract available
MeSH terms
Biosimilar Pharmaceuticals* / therapeutic use
Humans
Ranibizumab* / therapeutic use
Substances
Ranibizumab
Biosimilar Pharmaceuticals